Efficacy of Combining Ultrasound-Guided Needle Release of Transverse Carpal Ligament and Median Nerve Dextrose Water Hydrodissection for Carpal Tunnel Syndrome

Summary

Carpal tunnel syndrome (CTS) is a common musculoskeletal disorder, which is caused by compression of the median nerve as it travels through the wrist. There are several treatments for CTS, including conservative and surgical options. Though local corticosteroid injection has been considered more effective than physical therapy for treatment of CTS and has significant short-term benefits, long term benefits are not evidenced. Several studies in recent years reported significantly superior longer-term benefit of D5W and PRP compared with corticosteroid injections and other conservative managements. In addition, percutaneous release of the transverse carpal ligament (TCL) was developed to treat CTS in recent years. Because the effectiveness of the recently developed techniques in treating CTS has not been well established, the investigators aim to investigate whether combining US-guided partial release of the transverse carpal ligament with a needle plus D5W hydrodissection is more beneficial for CTS comparing to either treatment alone.

Conditions

• Carpal Tunnel Syndrome
• Dextrose
• Carpal Tunnel Release
• Ultrasound
• Nerve Hydrodissection Therapy

Interventions

PROCEDURE

Active Comparator: US-guided D5W perineural hydrodissection alone, group A

Patients in the group A will receive 1 session of ultrasound-guided perineural injection with 5ml D5W.

PROCEDURE

Active Comparator: US guided partial release of the TCL with a needle + D5W injection (to TCL), group B

Patients in the group B will receive 1 session of ultrasound-guided partial release of the TCL with a needle plus D5W injection to TCL.

PROCEDURE

Active Comparator: US-guided partial release of the TCL with D5W injection to TCL plus D5W perineural hydrodissection, group C

Patients in the group C will receive 1 session of the treatment combining group A and group B. Hydrodissection of the median nerve will be performed before TCL release.

Sponsors & Collaborators

• Shin Kong Wu Ho-Su Memorial Hospital

  lead OTHER

Principal Investigators

• Lin-Fen Hsieh · Shin Kong Wu Ho-Su Memorial Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-01

Primary Completion

2028-12-31

Completion

2030-12-31

Countries

• Taiwan

Study Locations